ESR1 and breast carcinoma: A large validation study comparing registry reports of ER and PR status to those of a single “expert” laboratory showed high concordance for ER+/PR+ and ER–/PR– and only small differences in risk estimates for ER+/PR+ and ER–/PR– breast cancers [70].